Brought to you by 
Sinovant gets Chinese rights to Angion's Phase III BB3
15 Jul 2019
Executive Summary
Angion Biomedica Corp. granted Sinovant Sciences Ltd. exclusive rights to develop and sell its hepatocyte growth factor agonist BB3 in China, Hong Kong, Macau, and Taiwan.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sinovant gets Chinese rights to Angion's Phase III BB3
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice